Replies to post #3781 on Isodiol International Inc (ISOLF)

[MarketProphet]

VANCOUVER, British Columbia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce the Company’s entrance into the vaping industry by signing a Letter of Intent (“LOI”) to acquire Bradley’s Bioscience Inc., a leading manufacturer and distributer of hemp oil and nicotine e-liquids.
Bradley’s Bioscience entered the vaping market with its nicotine e-liquids, created to serve as an innovative reduced-risk product compared to traditional cigarettes. Through this agreement, the company will expand its product offerings to include non-CBD lines, hemp oil vaping e-liquids, THC additives, and organic men’s grooming products.
“The global e-cigarette and vaping market is poised to be a $61.4 billion-dollar industry by 2025, and there is a definite need for standardization in the industry,” said Marcos Agramont, CEO of Isodiol. “This acquisition gives Isodiol the ability to penetrate a new market segment, where we can continue to provide consumers with high-quality products including a safer alternative to smoking.”
Bradley’s Bioscience manufactures more than 500+ nicotine products across several brands; all of which are compliant with current FDA regulations and approved for sale in both the United States and internationally. 
“Isodiol has played a pivotal role in our success over the years, by providing us and our private label consumers with the security of top tier products, supply chain consistency, a wealth of expanding knowledge and a solid support network,” said Joe Bradley, CEO of Bradley’s Bioscience. “I look forward to strengthening our brands across all industries to benefit consumers and I am confident that our products effect lives in a positive way. By partnering with Isodiol, we will be able to scale our business and grow our distribution channels across the United States and into International markets.”
For more information on Isodiol, please visit www.isodiol.com 
For more information on Bradley’s Bioscience, please visit www.bradleysbrand.com 
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol 
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
[e-mail]
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
[e-mail]

[Stingray]

In that case you have 2 choices...hope for the best near term and get a few $$s back....or take the tax write off and move on...